AR123127A1 - Compuestos y métodos de uso - Google Patents
Compuestos y métodos de usoInfo
- Publication number
- AR123127A1 AR123127A1 ARP210102152A ARP210102152A AR123127A1 AR 123127 A1 AR123127 A1 AR 123127A1 AR P210102152 A ARP210102152 A AR P210102152A AR P210102152 A ARP210102152 A AR P210102152A AR 123127 A1 AR123127 A1 AR 123127A1
- Authority
- AR
- Argentina
- Prior art keywords
- 6alkyl
- heterocyclylalkyl
- cycloalkylalkyl
- arylalkyl
- heteroarylalkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 11
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 11
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 11
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 10
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 abstract 9
- 125000005843 halogen group Chemical group 0.000 abstract 9
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004452 carbocyclyl group Chemical group 0.000 abstract 2
- -1 heteroararylalkyl Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- XGHKMTATADPCHI-UHFFFAOYSA-N 2-cyano-5-[[2-(5-methyl-2-phenylpiperidin-1-yl)-2-oxoacetyl]amino]pyridine-3-carboxamide Chemical compound CC(CCC1C2=CC=CC=C2)CN1C(C(NC1=CC(C(N)=O)=C(C#N)N=C1)=O)=O XGHKMTATADPCHI-UHFFFAOYSA-N 0.000 abstract 1
- QNFWQMMBZVIQKE-UHFFFAOYSA-N 5-[[2-[5-methyl-2-(4-methylphenyl)piperidin-1-yl]-2-oxoacetyl]amino]pyridine-3-carboxamide Chemical compound CC(CCC1C2=CC=C(C)C=C2)CN1C(C(NC1=CC(C(N)=O)=CN=C1)=O)=O QNFWQMMBZVIQKE-UHFFFAOYSA-N 0.000 abstract 1
- 101100516040 Caenorhabditis elegans nra-2 gene Proteins 0.000 abstract 1
- 101100133786 Caenorhabditis elegans nra-4 gene Proteins 0.000 abstract 1
- ZBSUGHHBVRQXAS-UHFFFAOYSA-N N-(5,6-dimethylpyridin-3-yl)-2-[5-methyl-2-[4-(2H-tetrazol-5-yl)phenyl]piperidin-1-yl]-2-oxoacetamide Chemical compound CC(CCC1C(C=C2)=CC=C2C2=NNN=N2)CN1C(C(NC1=CC(C)=C(C)N=C1)=O)=O ZBSUGHHBVRQXAS-UHFFFAOYSA-N 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 101150007570 nra-1 gene Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003053 piperidines Chemical class 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 125000003003 spiro group Chemical group 0.000 abstract 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063059959P | 2020-07-31 | 2020-07-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123127A1 true AR123127A1 (es) | 2022-11-02 |
Family
ID=78000758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102152A AR123127A1 (es) | 2020-07-31 | 2021-08-02 | Compuestos y métodos de uso |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US11492350B2 (https=) |
| EP (1) | EP4188920A1 (https=) |
| JP (1) | JP2023536589A (https=) |
| KR (1) | KR20230094196A (https=) |
| CN (1) | CN116568677A (https=) |
| AR (1) | AR123127A1 (https=) |
| AU (1) | AU2021319201A1 (https=) |
| CA (1) | CA3176912A1 (https=) |
| IL (1) | IL300147A (https=) |
| MX (1) | MX2023001379A (https=) |
| WO (1) | WO2022026892A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
| US12403137B2 (en) | 2019-10-28 | 2025-09-02 | Tango Therapeutics, Inc. | Compounds and methods of use |
| WO2022026892A1 (en) | 2020-07-31 | 2022-02-03 | Tango Therapeutics, Inc. | Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers |
| KR20240148320A (ko) * | 2021-12-17 | 2024-10-11 | 탱고 테라퓨틱스, 인크. | N-(6-아미노-5-메틸피리딘-3-일)-2-(벤조[d]티아졸-5-일)-5-메틸피페리딘-1-일)-2-옥소아세트아마이드의결정질 형태, 약제학적 조성물 및 이의 사용 방법 |
| EP4469438A1 (en) * | 2022-01-26 | 2024-12-04 | Tango Therapeutics, Inc. | Compounds and methods of use |
| EP4469447A1 (en) * | 2022-01-26 | 2024-12-04 | Tango Therapeutics, Inc. | Compounds and methods of use |
| JP2025504916A (ja) * | 2022-01-26 | 2025-02-19 | タンゴ セラピューティクス， インコーポレイテッド | 化合物及び使用方法 |
| WO2023146991A1 (en) * | 2022-01-26 | 2023-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
| WO2024022433A1 (zh) * | 2022-07-28 | 2024-02-01 | 北京望实智慧科技有限公司 | Prmt5抑制剂 |
| AU2023327684A1 (en) | 2022-08-15 | 2025-03-20 | Astrazeneca Ab | Mta-cooperative prmt5 inhibitors for use in the treatment of cancer |
| CN119744263A (zh) * | 2022-08-19 | 2025-04-01 | 北京望实智慧科技有限公司 | Prmt5抑制剂 |
| CN119731162A (zh) * | 2022-08-19 | 2025-03-28 | 北京望实智慧科技有限公司 | Prmt5抑制剂 |
| CN117658980A (zh) * | 2022-09-08 | 2024-03-08 | 郑州同源康医药有限公司 | 双环类prmt5抑制剂 |
| AU2023366908A1 (en) * | 2022-10-25 | 2025-05-08 | Tango Therapeutics, Inc. | Crystalline forms, pharmaceutical compositions and methods of use thereof |
| WO2024104244A1 (zh) * | 2022-11-15 | 2024-05-23 | 四川科伦博泰生物医药股份有限公司 | 草酸酰胺化合物、包含其的药物组合物及其制备方法和用途 |
| WO2024131918A1 (zh) * | 2022-12-22 | 2024-06-27 | 成都苑东生物制药股份有限公司 | 一种取代草酰胺类衍生物、其制备方法及用途 |
| CN120476118A (zh) * | 2023-01-17 | 2025-08-12 | 苏州浦合医药科技有限公司 | Prmt5-mta抑制剂 |
| CN118103373A (zh) | 2023-01-18 | 2024-05-28 | 上海德琪医药科技有限公司 | Prmt5抑制化合物和其用途 |
| CN120457129A (zh) * | 2023-01-31 | 2025-08-08 | 四川科伦博泰生物医药股份有限公司 | 草酸二酰胺化合物、包含其的药物组合物及其制备方法和用途 |
| WO2024170488A1 (en) | 2023-02-13 | 2024-08-22 | Astrazeneca Ab | Prmt5 inhibitor for use in cancer therapy |
| WO2025016323A1 (zh) | 2023-07-14 | 2025-01-23 | 江苏亚虹医药科技股份有限公司 | 蛋白质精氨酸酶甲基转移酶-5抑制剂及其医药用途 |
| TW202521525A (zh) | 2023-08-09 | 2025-06-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 雜芳基化合物、其製備方法及其在醫藥上的應用 |
| WO2025039979A1 (zh) | 2023-08-18 | 2025-02-27 | 江苏亚虹医药科技股份有限公司 | 蛋白质精氨酸酶甲基转移酶-5抑制剂及其医药用途 |
| WO2025059579A1 (en) | 2023-09-15 | 2025-03-20 | Ideaya Biosciences, Inc. | Methods of treating mat2a related diseases |
| WO2025064750A1 (en) | 2023-09-20 | 2025-03-27 | Ideaya Biosciences, Inc. | Combination therapy with a parg inhibitor |
| WO2025072544A1 (en) | 2023-09-27 | 2025-04-03 | Ideaya Biosciences, Inc. | Sulfonamino indazole compounds as inhibitors of parg |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| CN120309628A (zh) * | 2024-01-13 | 2025-07-15 | 艾立康药业股份有限公司 | 一种prmt5抑制剂及其组合物和药物用途 |
| WO2025166186A1 (en) * | 2024-01-31 | 2025-08-07 | Tango Therapeutics, Inc. | Crystalline forms, pharmaceutical compositions and methods of use thereof |
| WO2025166308A1 (en) | 2024-01-31 | 2025-08-07 | Tango Therapeutics, Inc. | Crystalline forms, pharmaceutical compositions and methods of use thereof |
| WO2025217297A1 (en) | 2024-04-09 | 2025-10-16 | Tango Therapeutics, Inc. | Prmt5 inhibitors for use in methods of treating mta-accumulating cancer |
| WO2025218671A1 (en) * | 2024-04-16 | 2025-10-23 | Shanghai Apeiron Therapeutics Company Limited | Novel prmt5 proteolysis targeting chimeric molecules and associated methods of use |
| CN121021512A (zh) * | 2024-05-28 | 2025-11-28 | 艾立康药业股份有限公司 | 一类prmt5抑制剂及其组合物和用途 |
| WO2025260063A2 (en) | 2024-06-13 | 2025-12-18 | Tango Therapeutics, Inc. | Methods of preparing a prmt5 inhibitor |
| WO2026067820A1 (zh) * | 2024-09-30 | 2026-04-02 | 江苏恒瑞医药股份有限公司 | 螺杂环类化合物、其制备方法及其在医药上的应用 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69622148T2 (de) | 1995-09-28 | 2002-10-31 | Suntory Limited, Osaka | Chinazozin derivate und deren verwendung |
| WO2004096774A1 (en) | 2003-05-01 | 2004-11-11 | Glaxo Group Limited | Acyl isoindoline derivatives and acyl isoquinoline derivatives as anti-viral agents |
| WO2012058645A1 (en) * | 2010-10-29 | 2012-05-03 | Biogen Idec Ma Inc. | Heterocyclic tyrosine kinase inhibitors |
| DK2935222T3 (en) | 2012-12-21 | 2019-01-07 | Epizyme Inc | PRMT5 INHIBITORS AND APPLICATIONS THEREOF |
| CA2899363A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| US20170210751A1 (en) | 2014-06-25 | 2017-07-27 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| EP3191592A1 (en) | 2014-09-11 | 2017-07-19 | Novartis AG | Inhibition of prmt5 to treat mtap-deficiency-related diseases |
| US20170280720A1 (en) | 2014-09-17 | 2017-10-05 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| WO2016089883A1 (en) | 2014-12-01 | 2016-06-09 | Novartis Ag | Compositions and methods for diagnosis and treatment of prostate cancer |
| GB201604020D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| JP6832430B2 (ja) * | 2016-08-31 | 2021-02-24 | アジオス ファーマシューティカルズ， インコーポレイテッド | 細胞代謝過程の阻害剤 |
| WO2018039972A1 (en) * | 2016-08-31 | 2018-03-08 | Agios Pharmaceuticals, Inc. | Inhibitors of cellular metabolic processes |
| EP3939986A1 (en) | 2017-08-09 | 2022-01-19 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| US20190083482A1 (en) | 2017-09-18 | 2019-03-21 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| WO2019084470A1 (en) | 2017-10-26 | 2019-05-02 | Prelude Therapeutics, Incorporated | SELECTIVE INHIBITORS OF THE PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) |
| EP3706747B1 (en) | 2017-11-08 | 2025-09-03 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| US10947234B2 (en) | 2017-11-08 | 2021-03-16 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| PT3704120T (pt) | 2017-11-24 | 2024-07-03 | Jubilant Episcribe Llc | Compostos heterocíclicos como inibidores de prmt5 |
| JP2021505583A (ja) | 2017-12-05 | 2021-02-18 | エンジェクス ファーマシューティカル インコーポレイテッド | Ｐｍｒｔ５阻害剤としての複素環式化合物 |
| US11059850B2 (en) | 2017-12-08 | 2021-07-13 | Janssen Pharmaceutica Nv | Spirobicyclic analogues |
| US20190175526A1 (en) | 2017-12-13 | 2019-06-13 | Macau University Of Science And Technology | Methods for treating cancer |
| US10278955B1 (en) | 2017-12-13 | 2019-05-07 | Macau University Of Science And Technology | Methods of treating cancer |
| SMT202200396T1 (it) | 2017-12-13 | 2022-11-18 | Lupin Ltd | Composti eterociclici biciclici sostituiti come inibitori di prmt5 |
| CA3091041A1 (en) | 2018-02-22 | 2019-08-29 | Ichan School Of Medicine At Mount Sinai | Protein arginine methyltransferase 5 (prmt5) degradation / disruption compounds and methods of use |
| KR102522856B1 (ko) | 2018-03-09 | 2023-04-19 | 파마블럭 사이언시스 (난징), 인코포레이티드 | 단백질 아르기닌 메틸전이효소 5(prmt 5)의 억제제, 이의 약학적 제품 및 이의 방법 |
| WO2019180628A1 (en) | 2018-03-22 | 2019-09-26 | Aurigene Discovery Technologies Limited | Imidazolidin-2-one compounds as prmt5 modulators |
| BR112020019111A2 (pt) | 2018-03-22 | 2021-01-12 | Aurigene Discovery Technologies Limited | Derivados de imidazolidin-2-ona substituída como inibidores de prmt5 |
| WO2019219805A1 (en) | 2018-05-16 | 2019-11-21 | Ctxone Pty Ltd | Combination therapy |
| US20210267973A1 (en) | 2018-05-31 | 2021-09-02 | Glaxosmithkline Intellectual Property Development Limited | Combination of a type ii protein arginine methyltransferase inhibitor and an icos binding protein to treat cancer |
| US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
| CA3118175A1 (en) | 2018-11-08 | 2020-05-14 | Glaxosmithkline Intellectual Property Development Limited | Combination of prmt5 inhibitors and bcl-2 inhibitors |
| LT3902803T (lt) * | 2018-12-27 | 2023-04-25 | Les Laboratoires Servier | Aza-heterobicikliniai mat2a inhibitoriai ir būdai, skirti panaudoti vėžio gydymui |
| EP3924360A1 (en) | 2019-02-13 | 2021-12-22 | Prelude Therapeutics, Incorporated | Selective inhibitor of protein arginine methyltransferase 5 (prmt5) |
| CN113330009B (zh) | 2019-03-12 | 2024-02-09 | 四川科伦博泰生物医药股份有限公司 | 氮杂环化合物、其制备方法及用途 |
| IL318073A (en) | 2019-03-25 | 2025-02-01 | California Inst Of Techn | PRMT5 inhibitors and their uses |
| WO2020198601A1 (en) | 2019-03-27 | 2020-10-01 | University Of Virginia Patent Foundation | Combinatorial drug treatment of cancer |
| WO2020205660A1 (en) | 2019-03-29 | 2020-10-08 | University Of Florida Research Foundation, Incorporated | Prmt5 inhibitor compounds |
| MA55556A (fr) | 2019-04-02 | 2022-02-09 | Aligos Therapeutics Inc | Composés ciblant prmt5 |
| WO2020206289A1 (en) | 2019-04-05 | 2020-10-08 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 |
| WO2020206308A1 (en) | 2019-04-05 | 2020-10-08 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 |
| JP2022526604A (ja) | 2019-04-05 | 2022-05-25 | プレリュード・セラピューティクス・インコーポレイテッド | タンパク質アルギニンメチルトランスフェラーゼ５の選択的阻害剤 |
| GB201905780D0 (en) | 2019-04-25 | 2019-06-05 | La Thangue Nicholas | Cancer therapy |
| WO2021004547A1 (en) | 2019-07-11 | 2021-01-14 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heterocyclic compounds as inhibitors of hpk1 |
| WO2021126731A1 (en) | 2019-12-17 | 2021-06-24 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| US20230062119A1 (en) | 2019-12-17 | 2023-03-02 | Merck Sharp & Dohme Llc | Use of biomarkers in identifying patients that will be responsive to treatment with a prmt5 inhibitor |
| CN114929234A (zh) | 2020-01-07 | 2022-08-19 | 辉瑞公司 | 用于治疗银屑病及其他自体免疫性病况的方法中的prmt5抑制剂 |
| WO2021163344A1 (en) | 2020-02-12 | 2021-08-19 | Amgen Inc. | Novel prmt5 inhibitors |
| WO2022026892A1 (en) * | 2020-07-31 | 2022-02-03 | Tango Therapeutics, Inc. | Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers |
| WO2022115377A1 (en) | 2020-11-24 | 2022-06-02 | Amgen Inc. | Tricyclic carboxamide derivatives as prmt5 inhibitors |
| UY39565A (es) | 2020-12-16 | 2022-06-30 | Amgen Inc | Inhibidores de prmt5 novedosos |
| EP4347569A4 (en) | 2021-06-02 | 2025-03-26 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a type ii prmt inhibitor |
| WO2023098439A1 (zh) | 2021-11-30 | 2023-06-08 | 上海和誉生物医药科技有限公司 | 一种吡唑衍生物，其制备方法和在药学上的应用 |
| CN116462677A (zh) | 2022-01-20 | 2023-07-21 | 上海和誉生物医药科技有限公司 | 一种多稠环prmt5抑制剂及其制备方法和应用 |
| CN116462676A (zh) | 2022-01-20 | 2023-07-21 | 上海和誉生物医药科技有限公司 | 一种多稠环prmt5抑制剂及其制备方法和应用 |
-
2021
- 2021-07-30 WO PCT/US2021/044004 patent/WO2022026892A1/en not_active Ceased
- 2021-07-30 IL IL300147A patent/IL300147A/en unknown
- 2021-07-30 CA CA3176912A patent/CA3176912A1/en active Pending
- 2021-07-30 KR KR1020237006890A patent/KR20230094196A/ko active Pending
- 2021-07-30 JP JP2023507253A patent/JP2023536589A/ja active Pending
- 2021-07-30 EP EP21783067.8A patent/EP4188920A1/en active Pending
- 2021-07-30 MX MX2023001379A patent/MX2023001379A/es unknown
- 2021-07-30 CN CN202180067678.XA patent/CN116568677A/zh active Pending
- 2021-07-30 AU AU2021319201A patent/AU2021319201A1/en active Pending
- 2021-08-02 AR ARP210102152A patent/AR123127A1/es unknown
- 2021-11-12 US US17/525,692 patent/US11492350B2/en active Active
-
2022
- 2022-04-29 US US17/732,846 patent/US11999727B2/en active Active
-
2024
- 2024-02-01 US US18/430,456 patent/US12264154B2/en active Active
- 2024-02-01 US US18/430,429 patent/US12304907B2/en active Active
-
2025
- 2025-02-20 US US19/058,661 patent/US20260078117A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220127256A1 (en) | 2022-04-28 |
| US20260078117A1 (en) | 2026-03-19 |
| US20240228478A1 (en) | 2024-07-11 |
| US12304907B2 (en) | 2025-05-20 |
| WO2022026892A1 (en) | 2022-02-03 |
| JP2023536589A (ja) | 2023-08-28 |
| US20240279219A1 (en) | 2024-08-22 |
| US12264154B2 (en) | 2025-04-01 |
| EP4188920A1 (en) | 2023-06-07 |
| KR20230094196A (ko) | 2023-06-27 |
| US11999727B2 (en) | 2024-06-04 |
| CN116568677A (zh) | 2023-08-08 |
| MX2023001379A (es) | 2023-06-15 |
| AU2021319201A1 (en) | 2023-02-16 |
| US20230113778A1 (en) | 2023-04-13 |
| TW202220970A (zh) | 2022-06-01 |
| CA3176912A1 (en) | 2022-02-03 |
| US11492350B2 (en) | 2022-11-08 |
| IL300147A (en) | 2023-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR123127A1 (es) | Compuestos y métodos de uso | |
| PE20200935A1 (es) | Compuestos derivados de 2-((bifenil)pirrolidin o piperidin) sulfonamida o carboxamida agonistas de receptores de orexina 2 | |
| AR109805A1 (es) | Derivados de oxadiazol microbiocidas | |
| AR094452A1 (es) | COMPUESTOS HETEROCÍCLICOS SUSTITUIDOS CON AMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O INFa | |
| JP2016536363A5 (https=) | ||
| AR098147A1 (es) | Composiciones herbicidas que contienen amidas de ácido n-(1,3,4-oxadiazol-2-il)arilcarboxílico | |
| AR099823A1 (es) | Compuestos bicíclicos de 7 eslabones | |
| AR089865A1 (es) | Derivados de bencimidazol e imidazopiridinas como moduladores de canales de sodio | |
| AR105845A1 (es) | Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4 | |
| JP2016536364A5 (https=) | ||
| AR107170A1 (es) | Compuestos heterocíclicos tricíclicos condesados como inhibidores de integrasa del vih | |
| AR062928A1 (es) | Inhibidores de la actividad quinasa utiles en el tratamiento de trastornos mediados por mecanismos de ikk2 | |
| AR103252A1 (es) | Compuestos de quinazolina | |
| AR113929A1 (es) | Compuestos heterocíclicos | |
| RU2016122093A (ru) | Замещенные бензамиды для борьбы с членистоногими | |
| AR095423A1 (es) | 2-azabiciclos sustituidos y su uso como moduladores del receptor de orexina | |
| AR097082A1 (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
| AR096450A1 (es) | Compuestos para la modulación de quinasas, y sus indicaciones | |
| AR094496A1 (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
| AR111756A1 (es) | 4-difluorometilbenzoilamidas de acción herbicida | |
| AR107321A1 (es) | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos | |
| PE20190806A1 (es) | Agonistas heterociclicos del receptor de apelina (apj) y usos de los mismos | |
| AR068115A1 (es) | Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida | |
| PE20161444A1 (es) | 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina | |
| AR110282A1 (es) | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 |